Product Description
VL#FIA3-30 is a preparation intended for topical use, applied on the penis, for the treatment of ED. VasoLead's preparation to treat erectile dysfunction (ED), VL#FIA3-30, is composed of 2 active pharmaceutical ingredients, both act as vasodilators via different mechanisms. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02496845)
Mechanisms of Action: ADRA1 Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: VasoLead (2012)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
VL#FIA3-30 #002 | P2 |
Unknown status |
Erectile Dysfunction |
2015-11-01 |